Eptifibatide Injection, Solution
Product Images NDC 52958-040

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Eptifibatide (NDC 52958-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hainan Shuangcheng Pharmaceuticals Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Ept 1)

FDA Label Image

Image Description (Ept 2)

This appears to be a chart displaying the percent of patients with events for two treatments over a period of time (in days). The treatments are "Eptifibatide" and "Placebo." The chart shows that, after 20 days, the percent of patients with events is significantly lower for the Eptifibatide treatment (approximately 10%) compared to the Placebo treatment (approximately 14%). However, it is difficult to determine what type of events are being measured without further context.*

FDA Label Image

Image Description (Ept 3)

This is a description of a medication called Eptifibatide, which is administered via injection. It comes in a single-dose vial containing 20 mg of the medication per 10 ml of solution, with a total volume of 110 mL. The manufacturer is Hainan Shuangeheng Pharmaceuticals Co. Ltd. located in China, and it is distributed in the United States by Athenes, based in Schaumburg IL. The medication is intended for intravenous use only and is used for weight-adjusted bolus dosing. Storage directions advise to keep it refrigerated and it is recommended to use within three months from the date of production, and to discard any unused portions.*

FDA Label Image

Ept 4

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.